Professor Michelle Haber AM
BSc (Psych) (Hons), PhD, Hon DSc (UNSW) FAHMS, Executive Director; Head of Program, Experimental Therapeutics
Professor Haber joined Children’s Cancer Institute as a staff scientist in 1984. She was appointed Director of the Institute in June 2000 and Executive Director in June 2003. Professor Haber is known for her world-class research into the treatment of neuroblastoma and acute lymphoblastic leukaemia in children.
Professor Haber holds a conjoint appointment as Professor in the Faculty of Medicine at the University of New South Wales. She has served as President (2010-2012) and currently serves on the Steering Committee of the International Advances in Neuroblastoma Research Association.
In 2007 Professor Haber was appointed a Member of the Order of Australia for services to science in the field of research into childhood cancer, to scientific education and to the community. In 2008, she was awarded an Honorary Doctorate from the University of New South Wales for her eminent service to the cancer research community. More recently, in 2014, Professor Haber was awarded the Cancer Institute NSW’s Premier’s Award for Outstanding Cancer Researcher of the Year and in 2015, was made a Fellow of the Australian Academy of Health and Medical Sciences.
Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma.
Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M
N Engl J Med. 1996 Jan 25;334(4):231-8. PMID: 8532000
Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma.
Burkhart CA, Cheng AJ, Madafiglio J, Kavallaris M, Mili M, Marshall GM, Weiss WA, Khachigian LM, Norris MD, Haber M
J Natl Cancer Inst. 2003 Sep 17;95(18):1394-403. PMID: 13130115
Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.
Haber M, Smith J, Bordow SB, Flemming C, Cohn SL, London WB, Marshall GM, Norris MD
J Clin Oncol. 2006 Apr 1;24(10):1546-53. PMID: 16575006
Hogarty MD, Norris MD, Davis K, Liu X, Evageliou NF, Hayes CS, Pawel B, Guo R, Zhao H, Sekyere E, Keating J, Thomas W, Cheng NC, Murray J, Smith J, Sutton R, Venn N, London WB, Buxton A, Gilmour SK, Marshall GM, Haber M
Cancer Res. 2008 Dec 1;68(23):9735-45. PMID: 19047152
Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma.
Burkhart CA, Watt F, Murray J, Pajic M, Prokvolit A, Xue C, Flemming C, Smith J, Purmal A, Isachenko N, Komarov PG, Gurova KV, Sartorelli AC, Marshall GM, Norris MD, Gudkov AV, Haber M
Cancer Res. 2009 Aug 15;69(16):6573-80. PMID: 19654298
Fletcher JI, Haber M, Henderson MJ, Norris MD
Nat Rev Cancer. 2010 Feb;10(2):147-56. PMID: 20075923
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.
Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, Huskey N, Blelloch R, Haber M, Norris MD, Lengyel P, Hackett CS, Preiss T, Chetcuti A, Sullivan CS, Marcusson EG, Weiss W, L’Etoile N, Goga A
Nat Med. 2010 Oct;16(10):1134-40. PMID: 20871609
ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux.
Henderson MJ, Haber M, Porro A, Munoz MA, Iraci N, Xue C, Murray J, Flemming CL, Smith J, Fletcher JI, Gherardi S, Kwek CK, Russell AJ, Valli E, London WB, Buxton AB, Ashton LJ, Sartorelli AC, Cohn SL, Schwab M, Marshall GM, Perini G, Norris MD
J Natl Cancer Inst. 2011 Aug 17;103(16):1236-51. PMID: 21799180
N-Myc regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastoma.
Fletcher JI, Gherardi S, Murray J, Burkhart CA, Russell A, Valli E, Smith J, Oberthuer A, Ashton LJ, London WB, Marshall GM, Norris MD, Perini G, Haber M
Cancer Res. 2012 Feb 15;72(4):845-53. PMID: 22202125
High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH, Venn NC, van den Berg H, de Bont ES, Maarten Egeler R, Hoogerbrugge PM, Kaspers GJ, Bierings MB, van der Schoot E, van Dongen J, Law T, Cross S, Mueller H, de Haas V, Haber M, Révész T, Alvaro F, Suppiah R, Norris MD, Pieters R
Leukemia. 2013 Jul;27(7):1497-503. PMID: 23407458